# Forensic Dossier: Study Forensics: APJ agonist as pharmacological exercise mimetic

**Run ID:** `mc2_study-forensics-030_claude_haiku_bb13a3`  
**Task:** study-forensics-030 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-06T16:24:03.686441+00:00  
**Task Family:** mechanism_vs_evidence  
**Trap Type:** preclinical_to_therapeutic_leap  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **40.0/100** (margin: 0.0)
**Failure modes:** decorative_uncertainty, named_not_explained, unused_assumption, wrong_answer
**Forensic flags:** 3
**Consistency findings:** 4
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 0.0/30 | 0.7/8 | 4.8/8 | 4.3/6 | 3.6/6 | 6.0/6 | 4.8/8 | 8.0/8 | 1.5/10 | 8.5/10 | **40.0/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `overclaim` [x] (gold: `mechanism_vs_evidence`)
**Finding Recall:** 100%
**Matched Findings:** mechanism_not_demonstrated, conclusion_exceeds_results
**Extra Findings:** evidence_matches_claim, cautious_scope_control, none_or_minor, decorative_uncertainty, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: effect |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "overclaim"


## Forensic Flags

### Claude Haiku

- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "overclaim"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "overclaim"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "effect"


## Evidence Map

### Claude Haiku

**Correctness:** 0.0/30
  - (+) `final_answer`: "overclaim"
    _Agent's answer for correctness check_
  - Note: No match (got: overclaim)

**Support Strength:** 1.2/8
  - (+) `final_answer`: "overclaim"
    _Conclusion grounded by reasoning chain_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph confirms conclusion grounding

**Structural Reasoning:** 4.8/8
  - (+) `steps[5]`: "Checked for confounders: the combination therapy result (doubled weight loss with incretin) shows synergy but doesn't is"
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 4.3/6
  - (+) `assumptions[0]`: "The study is preclinical (mouse models) based on the text describing 'obese and diabetic mice' and 'heart-failure model'"
    _Most substantive assumption_
  - (-) `assumptions[0]`: "The study is preclinical (mouse models) based on the text describing 'obese and diabetic mice' and 'heart-failure model'"
    _Declared but unused in reasoning_
  - Note: 5/5 substantive assumptions
  - Note: 1 unused assumption(s)

**Uncertainty Handling:** 3.6/6
  - (+) `uncertainties[0]`: "Whether the company's full regulatory submission or scientific publication contains appropriate caveats not reflected in"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.78"
    _Stated confidence level_
  - (-) `uncertainties[0]`: "Whether the company's full regulatory submission or scientific publication contains appropriate caveats not reflected in"
    _Listed but never addressed in reasoning_
  - Note: 5 uncertainties (5 substantive)
  - Note: 1 decorative uncertainty(ies)

**Alternative Hypothesis Quality:** 6.0/6
  - (+) `alternative_hypotheses[0]`: "Solid study: If the preclinical work is rigorous and the company is appropriately cautious in framing this as 'preparing"
    _Most substantive alternative hypothesis_
  - Note: 3 alternative hypotheses considered
  - Note: 3/3 include rejection reasoning

**Self Monitoring Quality:** 4.8/8
  - (+) `self_check[1]`: "Did I miss that this might be appropriate early-stage reporting? Possibly — if the company is merely saying 'we have pro"
    _Most substantive self-verification step_
  - Note: 4 self-check items
  - Note: Self-check quality: 0 deep, 4 arithmetic, 0 fluff

**Mechanism Quality:** 1.5/10
  - Note: Names concept but does not describe mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.67, 588 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'mechanism_vs_evidence'
  - `final_answer`: "overclaim"
  - _Impacts: correctness_

**MAJOR:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Study classification incorrect: expected 'mechanism_vs_evidence', detected 'overclaim'
  - `final_answer`: "overclaim"
  - _Impacts: correctness_

**MODERATE:**
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Names the phenomenon but does not explain the causal mechanism
  - `final_answer`: "overclaim"
  - _Impacts: mechanism_quality_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Named concept(s) ['effect'] but mechanism not described
  - _Impacts: mechanism_quality, insight_depth_

**STYLISTIC:**
- **Unused Assumption** `[HEURISTIC]`: Assumption 'The study is preclinical (mouse models) based on the text de...' is declared but not referenced in reasoning
  - `assumptions[0]`: "The study is preclinical (mouse models) based on the text describing 'obese and diabetic mice' and '"
  - _Impacts: assumption_discipline_
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'Whether the company's full regulatory submission or scientif...' is listed but not addressed
  - `uncertainties[0]`: "Whether the company's full regulatory submission or scientific publication contains appropriate cave"
  - _Impacts: uncertainty_handling_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (1/20 content words)
  - `key_claims[0]`: "The primary overclaim: translating mouse efficacy in obesity, diabetes, and heart failure to a human"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/19 content words)
  - `key_claims[1]`: "Secondary overclaim: framing as a 'pharmacological exercise mimetic' without evidence that the drug "
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/13 content words)
  - `key_claims[2]`: "The combination therapy result (synergy with incretin) is interesting but does not isolate the agoni"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/11 content words)
  - `key_claims[3]`: "Absence of safety, tolerability, or pharmacokinetic data in the summary raises concerns about premat"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 13778ms

**Final Answer:** overclaim

**Confidence:** 0.78

**Assumptions:**
- The study is preclinical (mouse models) based on the text describing 'obese and diabetic mice' and 'heart-failure model'
- The company is making claims about human therapeutic potential based on animal data
- The results reported are accurate as stated
- No human efficacy or safety data are presented
- The 'exercise hormone' framing is the company's characterization, not necessarily validated

**Reasoning Steps:**
1. Identified that all evidence is from preclinical mouse models, not human studies
2. Noted the company claims the drug 'could serve as a pharmacological exercise mimetic' and is 'preparing to translate' to humans
3. Recognized that mouse models of obesity, diabetes, and heart failure have limited predictive validity for human disease
4. Assessed whether the leap from mouse efficacy to human therapeutic claims is supported by the evidence presented
5. Evaluated the framing of apelin as an 'exercise hormone system' — this is a mechanistic claim that may be accurate but is being used to justify human translation
6. Checked for confounders: the combination therapy result (doubled weight loss with incretin) shows synergy but doesn't isolate the agonist's contribution in humans
7. Noted absence of safety data, pharmacokinetics, or human-relevant dosing information

**Key Claims:**
- The primary overclaim: translating mouse efficacy in obesity, diabetes, and heart failure to a human therapeutic claim without human data. Mice respond to many interventions that fail in humans.
- Secondary overclaim: framing as a 'pharmacological exercise mimetic' without evidence that the drug recapitulates exercise physiology in humans. The apelin pathway may be involved in exercise response, but activating it pharmacologically may not be equivalent.
- The combination therapy result (synergy with incretin) is interesting but does not isolate the agonist's independent effect and may not translate to humans.
- Absence of safety, tolerability, or pharmacokinetic data in the summary raises concerns about premature translation claims.

**Alternative Hypotheses:**
- Solid study: If the preclinical work is rigorous and the company is appropriately cautious in framing this as 'preparing for' human trials (not claiming efficacy in humans), this could be legitimate early-stage research reporting
- Mechanism vs. evidence: The 'exercise mimetic' framing could be decorative — the drug may work through apelin/APJ signaling but not actually recapitulate exercise physiology in humans
- Correlation vs. causation: The combination therapy results don't prove the agonist alone causes the weight loss; the incretin interaction is not mechanistically isolated

**Uncertainties:**
- Whether the company's full regulatory submission or scientific publication contains appropriate caveats not reflected in this summary
- The quality of the preclinical study design (randomization, blinding, sample sizes, statistical power)
- Whether 'preparing to translate' means Phase 1 trials are imminent or merely planned
- The magnitude of effect sizes and whether they are clinically meaningful even if replicated in humans
- Whether the 'exercise hormone' label is scientifically justified or marketing language

**Self-Verification:**
- Did I overstate the problems? No — the core issue is genuine: preclinical mouse data do not support claims about human therapeutic potential. This is a standard translational gap.
- Did I miss that this might be appropriate early-stage reporting? Possibly — if the company is merely saying 'we have promising preclinical data and plan to test in humans,' that is reasonable. But the text says the drug 'could serve as' a therapeutic and frames it as an 'exercise mimetic,' which are stronger claims.
- Did I conflate the study quality with the claim quality? No — I focused on the epistemic gap between evidence (mice) and claims (humans), not on whether the mouse studies were well-designed.
- Should I have flagged mechanism vs. evidence more strongly? Yes, slightly — the 'exercise hormone' framing is a mechanism claim applied across species without evidence. This is a secondary issue but worth noting.

**Dimension Scores:**
- Correctness: 0.0/30 `..........`
- Support Strength: 0.7/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.3/6 `#######...`
- Uncertainty Handling: 3.6/6 `######....`
- Alternative Hypothesis Quality: 6.0/6 `##########`
- Self Monitoring Quality: 4.8/8 `######....`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 1.5/10 `#.........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **40.0/100**.

**Best per dimension:**
- Correctness: Claude Haiku (0.0/30)
- Support Strength: Claude Haiku (0.7/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.3/6)
- Uncertainty Handling: Claude Haiku (3.6/6)
- Alternative Hypothesis Quality: Claude Haiku (6.0/6)
- Self Monitoring Quality: Claude Haiku (4.8/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (1.5/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 13.8s | 40.0/100 | 2.9 |

Failure modes observed: decorative_uncertainty, named_not_explained, unused_assumption, wrong_answer.
